Wearable Injectors151

Issue No #151 Sep 2023 September 10th, 2023

Inside the magazine

YPSODOSE – THE CLINIC-READY 10 ML PATCH INJECTOR

Christian Esser Wiesemann

YPSODOSE – THE CLINIC-READY 10 ML PATCH INJECTOR

Christian Esser Wiesemann provides the latest insights into the prefilled and pre-assembled YpsoDose patch injector, which is now available for clinical trials.

A NEW FRONTIER: SELF-ADMINISTRATION OF LYOPHILISED, LARGE-VOLUME SUBCUTANEOUS BIOLOGICS

Enable Injections

A NEW FRONTIER: SELF-ADMINISTRATION OF LYOPHILISED, LARGE-VOLUME SUBCUTANEOUS BIOLOGICS

Mehul Desai and Daniel Waites discuss the pros and cons of lyophilisation for biologic injectable drugs, and how Enable Injections’ enFuse device can provide an answer to the challenges of self-injection of large-volume and lyophilised biologics.

PRODUCT SHOWCASE: COMPLETE SYSTEM FOR STANDARD-COMPLIANT TESTING OF WEARABLE INJECTORS

PRODUCT SHOWCASE: COMPLETE SYSTEM FOR STANDARD-COMPLIANT TESTING OF WEARABLE INJECTORS

Specifically tailored to on-body delivery systems (OBDSs) / wearable injectors, ZwickRoell showcases its customised, comprehensive solution for performing functional tests in accordance with the ISO 11608-6 standard.

SUSTAINABLE DESIGN OF A DRUG DELIVERY DEVICE FOR BIOPHARMACEUTICALS

SUSTAINABLE DESIGN OF A DRUG DELIVERY DEVICE FOR BIOPHARMACEUTICALS

Maike Wolf and Marie Stockton discuss how sustainability is a fundamental strategic priority for Gerresheimer. They also highlight how eco-design principles have been applied to the development of an on-body injector for subcutaneous delivery of biopharmaceuticals.

COMPARISON OF MECHATRONIC VS MECHANICAL WEARABLE DRUG DELIVERY SYSTEMS

COMPARISON OF MECHATRONIC VS MECHANICAL WEARABLE DRUG DELIVERY SYSTEMS

Thomas Mayer, Nicolas Bailo and Martin Liniger highlight some of the key challenges that mechanical and mechatronic drug delivery systems must overcome when delivering large volumes of biologics subcutaneously and explain the solutions that Sonceboz has considered during the development process of the company’s large-volume injector.

EXTENDING PATIENT-FRIENDLY DRUG DELIVERY TO HIGH-VOLUME WEARABLE DEVICES

Dr Iris Schnitzler

EXTENDING PATIENT-FRIENDLY DRUG DELIVERY TO HIGH-VOLUME WEARABLE DEVICES

Iris Schnitzler discusses the benefits of on-body delivery systems, including the flexibility and convenience they bring to patients managing chronic conditions, and how the Sorrel platform overcomes some of the inherent complexities and challenges of developing such a device. Dr Schnitzler then goes on to speak with Bas van Buijtenen and Andrei Yosef about the Sorrel platform and how its integration within LTS supports the company’s fundamental objectives of enabling partners and empowering patients.

THE VERTIVA™ ON-BODY DELIVERY SYSTEM: EXPANDING OPPORTUNITIES IN HOME-BASED CARE

Stevanato Group

THE VERTIVA™ ON-BODY DELIVERY SYSTEM: EXPANDING OPPORTUNITIES IN HOME-BASED CARE

Adam Stops introduces Vertiva™, Stevanato Group’s next-generation on-body delivery system platform, and discusses how it meets the needs of pharma companies looking to deliver large-volume doses in a patient-centric manner.

CHRONIC PATIENTS AT THE CENTRE OF LARGE-VOLUME SC DELIVERY WITH A SUSTAINABLE ON-BODY INJECTOR

CHRONIC PATIENTS AT THE CENTRE OF LARGE-VOLUME SC DELIVERY WITH A SUSTAINABLE ON-BODY INJECTOR

Cécile Gross and Mark Tunkel discuss the role of patient-centricity in the development of Nemera’s sustainable on-body injector platform.

Technology Showcase: CCBio’s Felice Dose – Simplifying Subcutaneous Infusion

Technology Showcase: CCBio’s Felice Dose – Simplifying Subcutaneous Infusion

CCBio showcases Felice Dose, a revolutionary on-body injector (OBI) designed to address the challenges of traditional IV injections and SC drug administration.

INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES

INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES

Roger Bohannan discusses the capabilities and design challenges of connected drug delivery devices.

INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT

Dave Beckstoffer

INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT

Dave Beckstoffer discusses the often overlooked importance of including motion system design considerations from the very earliest stages of wearable injector development, and how doing so can reduce costs, shorten timelines and improve patient outcomes.

DIRECTIONS FOR WEARABLE ON-BODY INJECTOR SYSTEMS AND BEYOND

DIRECTIONS FOR WEARABLE ON-BODY INJECTOR SYSTEMS AND BEYOND

Matt Parker, Karthik Chellappan and David Cottenden discuss the current state of play for large-volume injection and look into the challenges that on-body delivery systems currently in development will need to overcome to find success in a changing marketplace.

WOULD YOU LIKE TO GO LARGE? KEY CONSIDERATIONS FOR LARGE-VOLUME INJECTORS

WOULD YOU LIKE TO GO LARGE? KEY CONSIDERATIONS FOR LARGE-VOLUME INJECTORS

Malcolm Boyd discusses the factors that need to be considered early in the development of large-volume injectors, which will have a major influence on the performance, usability and cost of a device.

REUSABLE WEARABLE INJECTORS: LESSONS FROM IN VITRO DIAGNOSTICS

REUSABLE WEARABLE INJECTORS: LESSONS FROM IN VITRO DIAGNOSTICS

Thomas James explores how insights from the development of successful in vitro diagnostic instruments can help guide the evolution of wearable injectors.

BD INNOVATION FOR SUBCUTANEOUS DELIVERY OF LARGE-VOLUME COMPLEX BIOLOGICS

Beth McBride DiLauri

BD (Becton Dickinson & Company)

BD INNOVATION FOR SUBCUTANEOUS DELIVERY OF LARGE-VOLUME COMPLEX BIOLOGICS

Beth McBride DiLauri summarises the results of a clinical study on the BD Libertas™ Wearable Injector. The results position the device as a viable alternative to traditional intravenous administration.

Top